Cynthia N Oliver is a prominent inventor based in North Potomac, MD (US). She has made significant contributions to the field of medical formulations, particularly in the development of antibody formulations for respiratory syncytial virus (RSV). With a total of 12 patents to her name, her work has had a substantial impact on the treatment and prevention of RSV infections.

Latest Patents

One of her latest patents is focused on stabilized liquid anti-RSV antibody formulations. This invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment that immunospecifically binds to an RSV antigen. These formulations exhibit stability, low to undetectable levels of aggregation, and minimal loss of biological activity, even during extended storage periods. The formulations are designed to be substantially free of surfactants, inorganic salts, and other common excipients. Furthermore, the invention outlines methods for preventing, treating, or ameliorating symptoms associated with RSV infection using these innovative liquid formulations.

Career Highlights

Cynthia has worked with notable companies in the pharmaceutical industry, including MedImmune Limited and Arexis AB. Her experience in these organizations has contributed to her expertise in developing effective medical solutions.

Collaborations

Throughout her career, Cynthia has collaborated with esteemed colleagues such as Christian B Allan and Stephen T Chang. These partnerships have further enhanced her research and development efforts in the field.

Conclusion

Cynthia N Oliver's contributions to the field of medical formulations, particularly in the area of RSV treatment, highlight her innovative spirit and dedication to improving healthcare solutions. Her work continues to influence the development of effective therapies for respiratory infections.

This text is generated by artificial intelligence and may not be accurate.